2001
Preevaluation of Clinical Trial Data: The Case of Preemptive Cytomegalovirus Therapy in Patients with Human Immunodeficiency Virus
Paltiel A, Goldie S, Losina E, Weinstein M, Seage G, Kimmel A, Zhang H, Freedberg K. Preevaluation of Clinical Trial Data: The Case of Preemptive Cytomegalovirus Therapy in Patients with Human Immunodeficiency Virus. Clinical Infectious Diseases 2001, 32: 783-793. PMID: 11229847, DOI: 10.1086/319223.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAntiviral AgentsChemopreventionCost-Benefit AnalysisCytomegalovirusCytomegalovirus InfectionsGanciclovirHIV InfectionsHumansModels, BiologicalPolymerase Chain ReactionPredictive Value of TestsQuality-Adjusted Life YearsSensitivity and SpecificityValganciclovirConceptsHuman immunodeficiency virusDuration of survivalPreemptive therapyCMV casesImmunodeficiency virusCMV polymerase chain reactionEnd-stage HIV diseaseUpcoming trialsCMV preemptive therapySalvage antiretroviral therapyCells/microLClinical trial dataCMV prophylaxisAntiretroviral therapyHIV diseaseComplication rateEfficacy assumptionsPolymerase chain reactionDisease progressionClinical uncertaintyDrug effectsPatientsTrial dataTherapyChain reaction
1998
The Cost-Effectiveness of Preventing Cytomegalovirus Disease in AIDS Patients
Paltiel A, Freedberg K. The Cost-Effectiveness of Preventing Cytomegalovirus Disease in AIDS Patients. Interfaces 1998, 28: 34-51. DOI: 10.1287/inte.28.3.34.Peer-Reviewed Original ResearchIncidence of infectionLate-stage HIV diseaseToxicity of therapyNational cohort studyProgression of illnessCost-effectiveness resultsPrice of therapyCMV prophylaxisCytomegalovirus diseaseCytomegalovirus infectionHIV diseaseCohort studyPatients' qualityAIDS patientsClinical trialsNatural historyInfectionProphylaxisTherapyIncidenceDiseaseCompartmental modelPatientsIllnessProgressionA Monte Carlo Simulation of Advanced HIV Disease
Paltiel AD, Scharfstein JA, Seage GR, Losina E, Goldie SJ, Weinstein MC, Craven DE, Freedberg KA. A Monte Carlo Simulation of Advanced HIV Disease. Medical Decision Making 1998, 18: s93-s105. PMID: 9566470, DOI: 10.1177/0272989x98018002s11.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioMonte Carlo simulation frameworkDecision makersCost-effectiveness ratioQuality-adjusted monthsPrice assumptionsNet costLife yearsData estimatesCost-effective usePatient care resourcesState transition modelCare resourcesMakersAdvanced HIV diseaseSensitivity analysisLate-stage diseaseBaseline resultsAlternative interventionsQuality of lifeTreatment of AIDSCostCMV prophylaxisGanciclovir prophylaxis